Berlimatoxumab Antibody is a research-grade biosimilar monoclonal antibody targeting lukG. It is a human IgG1-kappa antibody. Reactivity: Staphylococcus aureus. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Berlimatoxumab (ASN-2) is an antibody. Berlimatoxumab can be used for experiment research. • Separately or combined, LukG/LukH is functionally unique compared to other staphylococcal bicomponent leukotoxins., PMID:24586678 • Molecular mechanism of leukocidin GH-integrin CD11b/CD18 recognition and species specificity., PMID:31852826 • Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies., PMID:27467113 • Structure-function analysis of heterodimer formation, oligomerization, and receptor binding of the Staphylococcus aureus bi-component toxin LukGH., PMID:25371205 • Adaptive laboratory evolution and independent component analysis disentangle complex vancomycin adaptation trajectories., PMID:35858453 • Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins., PMID:29459694 • Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics., PMID:20661294 • Serum neutralizing antibody after rabies postexposure prophylaxis., PMID:945973 • Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening., PMID:29176494 • Vitamin E regulates mitochondrial hydrogen peroxide generation., PMID:10490278
